Pfizer has emerged victorious in a legal brawl with Poland and Romania over contested COVID vaccine orders, with a Belgian ...
Zacks Investment Research on MSN
Why Pfizer (PFE) outpaced the stock market today
In the latest close session, Pfizer (PFE) was up +1.67% at $28.55. The stock outperformed the S&P 500, which registered a daily gain of 0.72%. Elsewhere, the Dow saw an upswing of 0.48%, while the ...
In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug ...
The combination of talazoparib and enzalutamide demonstrated a statistically significant improvement in radiographic ...
When Lyme disease makes the news, it's typically not for positive reasons — but Pfizer is gearing up to seek regulatory ...
Pfizer (NYSE: PFE) is one of the most widely held dividend stocks among retirement investors. The stock currently yields 6.3% ...
The U.S. Food and Drug Administration (“FDA”) accepted Celcuity’s New Drug Application (“NDA”) and granted Priority Review with a Prescription ...
Pfizer (NYSE:PFE) has quietly built momentum in 2026, with shares up 6.61% year-to-date and 2.70% over the past year. The ...
Pfizer said its experimental Lyme disease vaccine was more than 70% efficacious in reducing confirmed cases of the tickborne ...
Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated ...
Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary ...
12d
Pfizer to seek FDA approval for Lyme vaccine as CT report shows ticks are more abundant than ever
The annual tick report shows Lone Star ticks have established populations along Connecticut's shoreline, raising the risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results